- Home
- / Veloxis Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Veloxis Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
KR39.5 M
FY, 2018
CreditSafe Score
?
Score changed on Mar 21, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| DKK | FY, 2018 |
|---|---|
| Revenue | 39.5M |
| Cost of goods sold | 7.9M |
| Gross profit | 31.6M |
| Gross profit margin, % | 80.0% |
| Operating expense total | 37.2M |
| Depreciation and amortization | 193.0K |
| EBITDA | (5.6M) |
| EBITDA margin, % | -14.3% |
| EBIT | (5.8M) |
| EBIT margin, % | -14.8% |
| Interest income | 347.0K |
| Interest expense | 6.3M |
| Pre tax profit | (11.9M) |
| Income tax expense | (6.6M) |
| Net Income | (5.3M) |